Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment

Mario Giuliano(Regione Campania), Massimo Cristofanilli(Cornell University), Antonio Giordano(University of Siena), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Summer Jackson(The University of Texas MD Anderson Cancer Center), James M. Reuben(The University of Texas MD Anderson Cancer Center), Michal Mego(Comenius University Bratislava), Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Sabino De Placido, Vicente Valero(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), Ricardo H. Álvarez(The University of Texas MD Anderson Cancer Center), Kenneth R. Hess(The University of Texas MD Anderson Cancer Center), Beverly C. Handy(The University of Texas MD Anderson Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center)
Breast Cancer Research
June 15, 2011
10.1186/bcr2907
Cited by 224

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k